Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1987 1
1990 1
1991 7
1992 3
1993 6
1994 3
1995 8
1996 5
1997 7
1998 7
1999 7
2000 10
2001 14
2002 18
2003 13
2004 16
2005 21
2006 29
2007 18
2008 24
2009 20
2010 30
2011 45
2012 64
2013 54
2014 71
2015 60
2016 64
2017 41
2018 41
2019 32
2020 38
2021 70
2022 63
2023 64
2024 54
2025 62

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

965 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. André F, et al. Among authors: aksoy s. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. Lancet. 2023. PMID: 37086745 Clinical Trial.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Among authors: aksoy s. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Cancer Prevalence across Vertebrates.
Compton ZT, Mellon W, Harris VK, Rupp S, Mallo D, Kapsetaki SE, Wilmot M, Kennington R, Noble K, Baciu C, Ramirez LN, Peraza A, Martins B, Sudhakar S, Aksoy S, Furukawa G, Vincze O, Giraudeau M, Duke EG, Spiro S, Flach E, Davidson H, Li CI, Zehnder A, Graham TA, Troan BV, Harrison TM, Tollis M, Schiffman JD, Aktipis CA, Abegglen LM, Maley CC, Boddy AM. Compton ZT, et al. Among authors: aksoy s. Cancer Discov. 2025 Jan 13;15(1):227-244. doi: 10.1158/2159-8290.CD-24-0573. Cancer Discov. 2025. PMID: 39445720 Free PMC article.
Ribociclib-induced autoimmune-like hepatitis: a case report.
Kavgaci G, Sahin TK, Sokmensuer C, Balaban HY, Aksoy S. Kavgaci G, et al. Among authors: aksoy s. J Chemother. 2024 Nov 28:1-6. doi: 10.1080/1120009X.2024.2433368. Online ahead of print. J Chemother. 2024. PMID: 39610055
Tissue spaces are reservoirs of antigenic diversity for Trypanosoma brucei.
Beaver AK, Keneskhanova Z, Cosentino RO, Weiss BL, Awuoche EO, Smallenberger GM, Buenconsejo GY, Crilly NP, Smith JE, Hakim JMC, Zhang B, Bobb B, Rijo-Ferreira F, Figueiredo LM, Aksoy S, Siegel TN, Mugnier MR. Beaver AK, et al. Among authors: aksoy s. Nature. 2024 Dec;636(8042):430-437. doi: 10.1038/s41586-024-08151-z. Epub 2024 Oct 30. Nature. 2024. PMID: 39478231 Free PMC article.
Testicular epidermoid cyst.
Çakıroğlu B, Sönmez NC, Sinanoğlu O, Ateş L, Aksoy SH, Özcan F. Çakıroğlu B, et al. Among authors: aksoy sh. Afr J Paediatr Surg. 2015 Jan-Mar;12(1):89-90. doi: 10.4103/0189-6725.151002. Afr J Paediatr Surg. 2015. PMID: 25659561 Free PMC article.
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Tokat UM, Ulukan B, Cetin M, Calisir K, Gedik ME, Bal H, Sener Sahin O, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O. Saatci O, et al. Among authors: aksoy s. Cell Death Dis. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3. Cell Death Dis. 2024. PMID: 38879508 Free PMC article.
965 results